Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: J Neurooncol. 2018 Dec 7;141(2):327–335. doi: 10.1007/s11060-018-03034-6

Figure 2:

Figure 2:

Kaplan-Meier estimates of progression-free survival in all three LGG molecular groups (A/O/G) in relation to contrast enhancement. Out of 316 patients, 98 patients (31%) showed a contrast-enhancing tumor on their preoperative MR scans. No significant differences in PFS were observed when comparing the enhancing and non-enhancing gliomas.